Skip to Main Content

A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

Conditions

Diseases of the Nervous System | Immune System

Phase IB

What is the purpose of this trial?

Brief Summary:

This study is a multi center, open-label, study of ANX005 in combination with IVIg in subjects diagnosed with GBS.

  • Trial with
    Annexon, Inc.
  • Start Date
    10/15/2019
  • End Date
    09/29/2020
Trial Image

For more information about this study, contact:

Bailey Munro Sheldon

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    02/07/2020
  • Study HIC
    #2000025922